Clinical trials: psoriasis
Psoriasis, Moderate to Severe
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
- Trial name
- NCT00162253
- Testing
- BMS 587101
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03556202
- Testing
- Mirikizumab
- Where
- 229 sites in United States, Argentina and 17 more
- Volunteers
- 1,936 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants
The purpose of this study is to assess the PK comparability and compare safety and tolerability of DRL_AB administered via an auto injector (AI) or prefilled syringe (PFS) in healthy male participants.
- Trial name
- NCT07744828
- Testing
- DRL_AB
- Where
- 3 sites in New Zealand
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar…
- Trial name
- NCT00601107
- Testing
- Doxercalciferol
- Where
- 19 sites in United States
- Volunteers
- 111 people
- Sponsor
- Genzyme, a Sanofi Company
Moderate to Severe Plaque Psoriasis
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05342428
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Psoriasis
Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
- Trial name
- NCT00236119
- Testing
- CEP-701 20mg, CEP-701 40mg, CEP-701 60mg
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Cephalon
Moderate Plaque Psoriasis, Moderate Psoriasis
Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece
Psoriasis is a skin disorder wherein skin cells multiply faster than normal, making the skin itchy and look patchy and red. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.
- Conditions
- Moderate Plaque Psoriasis, Moderate Psoriasis, Psoriasis
- Trial name
- REDEFINE (NCT06247319)
- Where
- 22 sites in Greece
- Volunteers
- 250 people
- Sponsor
- AbbVie
Plaque Psoriasis
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.
- Trial name
- NCT02239666
- Testing
- NIS
- Where
- 106 sites in United States, France and 3 more
- Volunteers
- 899 people
- Sponsor
- AstraZeneca
Psoriasis
Efficacy of Novel Drug-combinations for Relief of Psoriasis
ENDURE is a prospective, observational study aimed to document clinical response and side effects associated with compounded psoriasis medications when prescribed as routine care.
- Trial name
- ENDURE (NCT02394301)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Medimix Specialty Pharmacy, LLC
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Psoriasis Vulgaris
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
A phase 4 trial comparing the safety and efficacy of treatment with Xamiol® gel (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with Daivonex® scalp solution (calcipotriol 50 mcg/g)…
- Trial name
- NCT02533973
- Testing
- Xamiol® gel, Daivonex® scalp solution
- Where
- China
- Volunteers
- 951 people
- Sponsor
- LEO Pharma
Psoriasis
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- CHAMPION (NCT00235820)
- Testing
- adalimumab, MTX
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Abbott
Psoriasis Vulgaris
PSOREAL - Managing PSOriasis in the REAL World
Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam…
- Trial name
- PSOREAL (NCT02935582)
- Testing
- Enstilar® aerosol foam, Other topical
- Where
- 3 sites in Canada, Sweden and 1 more
- Volunteers
- 1,214 people
- Sponsor
- LEO Pharma
Psoriasis
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy.
- Trial name
- TRANSIT (NCT01059773)
- Testing
- Ustekinumab, Methotrexate
- Where
- 76 sites in Austria, Belgium and 17 more
- Volunteers
- 490 people
- Sponsor
- Janssen-Cilag International NV
Psoriatic Arthritis
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety…
- Trial name
- NCT04713072
- Testing
- ABY-035
- Where
- 32 sites in Austria, Belgium and 5 more
- Volunteers
- 129 people
- Sponsor
- ACELYRIN Inc.
Psoriasis Vulgaris
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
- Trial name
- NCT02106195
- Testing
- Belumosudil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Kadmon Corporation, LLC
Plaque Psoriasis
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
This is a Phase I, randomized, placebo-controlled, single blind, parallel group, single-center study designed to evaluate immune responses during and after administration of 12 weekly SC doses of 1.0 mg/kg efalizumab in subjects…
- Trial name
- NCT00382512
- Testing
- Raptiva (efalizumab)
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
Plaque Psoriasis
Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis
The purpose of the study is to assess the safety and efficacy of an injectable biologic and U0279 as combination therapy compared to that of an injectable biologic alone for severe plaque-type psoriasis.
- Trial name
- NCT00832364
- Testing
- Acitretin (also called U0279), Etanercept
- Where
- 3 sites in United States
- Sponsor
- Stiefel, a GSK Company
Genital Psoriasis, Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
- Trial name
- IXORA-Q (NCT02718898)
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
This single arm study will evaluate the efficacy and safety of sequential treatment with Diavobet (betamethasone propionate 0.5mg/g plus calcipotriol hydrate 50 micrograms/g) once daily for 4 weeks followed by Daivonex…
- Trial name
- NCT00437619
- Testing
- calcipotriol hydrate [Daivonex]
- Where
- 10 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.